Proteome analysis of myocardial tissue following ischemia and reperfusion--effects of complement inhibition

Michael Buerke1, Hansjörg Schwertz, Tina Längin

  • 1Department of Medicine III, Martin-Luther-University, Ernst-Grube-Str. 40, 06097 Halle, Germany. michael.buerke@medizin.uni-halle.de

Insights

Blocking complement activation with a C1s inhibitor reduces myocardial ischemia-reperfusion injury. This novel approach preserves key cardiac proteins, offering significant cardioprotection by modulating inflammatory and cytoprotective pathways.

Area of Science:

  • Cardiology
  • Immunology
  • Proteomics

Background:

  • Myocardial ischemia-reperfusion injury involves complement activation, leading to inflammation and tissue damage.
  • Transcription factors like NF-kappaB and protein synthesis/degradation play crucial roles in this inflammatory process.

Purpose of the Study:

  • To investigate the cardioprotective effects of a novel C1s inhibitor in a rabbit model of myocardial ischemia-reperfusion injury.
  • To analyze cardiac protein expression changes and identify potential therapeutic targets.

Main Methods:

  • A rabbit model of myocardial ischemia (60 min) and reperfusion (180 min) was employed.
  • Two-dimensional electrophoresis and nanoHPLC/ESI-MS/MS were used for proteomic analysis.
  • A selective small molecule C1s inhibitor (C1s-INH-248) was administered prior to reperfusion.

Main Results:

  • C1s-INH-248 treatment significantly reduced myocardial injury, evidenced by diminished plasma creatine kinase activity.
  • Proteomic analysis identified 509 protein spots, with 480 consistently present across groups.
  • Key proteins including superoxide dismutase, alpha-crystallin, and troponin T were preserved in C1s-INH-248 treated animals compared to vehicle controls.

Conclusions:

  • Blocking the classical complement pathway via C1s inhibition provides significant cardioprotection.
  • This strategy preserves essential anti-inflammatory and cytoprotective proteins, mitigating ischemia-reperfusion injury.
  • C1s inhibitors represent a promising therapeutic approach for managing myocardial damage.